Endocyte Company Profile (NASDAQ:ECYT)

About Endocyte

Endocyte logoEndocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: ECYT
  • CUSIP: 29269A10
Key Metrics:
  • Previous Close: $2.07
  • 50 Day Moving Average: $2.26
  • 200 Day Moving Average: $2.77
  • 52-Week Range: $42,268,000.00 - $1.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.67
  • P/E Growth: 0.00
  • Market Cap: $86.23M
  • Outstanding Shares: 42,268,000
  • Beta: 1.84
Profitability:
  • Net Margins: -57,108.57%
  • Return on Equity: -25.17%
  • Return on Assets: -24.29%
Debt:
  • Current Ratio: 32.65%
  • Quick Ratio: 32.65%
Additional Links:
Companies Related to Endocyte:

Analyst Ratings

Consensus Ratings for Endocyte (NASDAQ:ECYT) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.50 (267.65% upside)

Analysts' Ratings History for Endocyte (NASDAQ:ECYT)
Show:
DateFirmActionRatingPrice TargetDetails
11/11/2016Credit Suisse GroupReiterated RatingBuy$7.00View Rating Details
5/4/2016Cowen and CompanyReiterated RatingBuyView Rating Details
5/4/2016WedbushReiterated RatingOutperform$8.00View Rating Details
11/4/2015Royal Bank of CanadaLower Price TargetOutperform$13.00 -> $10.00View Rating Details
9/8/2015Cantor FitzgeraldReiterated RatingBuy$21.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Endocyte (NASDAQ:ECYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017($0.25)N/AView Earnings Details
11/9/2016Q316($0.27)($0.21)$0.03 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.24)ViewListenView Earnings Details
3/2/2016Q4($0.27)($0.23)$0.01 millionViewListenView Earnings Details
11/3/2015Q315($0.27)($0.24)$0.03 millionViewN/AView Earnings Details
8/4/2015Q215($0.30)($0.25)ViewN/AView Earnings Details
5/7/2015Q115($0.24)($0.26)ViewN/AView Earnings Details
3/2/2015Q414($0.25)($0.19)$2.55 million$12.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.21)($0.14)$5.10 million$3.90 millionViewN/AView Earnings Details
7/29/2014Q214$0.10$0.52$26.62 million$49.17 millionViewN/AView Earnings Details
5/2/2014Q114($0.14)($0.09)$15.07 million$17.30 millionViewN/AView Earnings Details
2/24/2014Q413($0.14)($0.08)$15.90 million$17.30 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.06)($0.11)$14.24 million$14.50 millionViewN/AView Earnings Details
4/15/2013Q413($0.10)$8.50 million$13.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Endocyte (NASDAQ:ECYT)
Current Year EPS Consensus Estimate: $-1.02 EPS
Next Year EPS Consensus Estimate: $-1.22 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.29)($0.27)($0.28)
Q2 20162($0.29)($0.27)($0.28)
Q3 20162($0.30)($0.29)($0.30)
Q4 20161($0.26)($0.26)($0.26)
Q1 20171($0.32)($0.32)($0.32)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.33)($0.33)($0.33)
Q4 20171($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endocyte (NASDAQ:ECYT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Endocyte (NASDAQ:ECYT)
Insider Ownership Percentage: 16.62%
Institutional Ownership Percentage: 37.04%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/30/2016Christopher P. LeamonVPSell23,244$2.55$59,272.20View SEC Filing  
5/10/2016Philip S LowInsiderBuy11,375$3.52$40,040.00View SEC Filing  
1/19/2016Fred A. MiddletonDirectorBuy10,000$2.79$27,900.00View SEC Filing  
1/15/2016Fred A. MiddletonDirectorBuy20,000$2.80$56,000.00View SEC Filing  
4/9/2014Allen RitterVPSell1,000$21.16$21,160.00View SEC Filing  
3/21/2014Allen RitterVPSell8,000$33.11$264,880.00View SEC Filing  
2/14/2014Philip LowInsiderSell6,000$15.00$90,000.00View SEC Filing  
12/2/2013P Ron EllisCEOSell3,000$12.00$36,000.00View SEC Filing  
9/16/2013Allen RitterVPSell2,000$17.06$34,120.00View SEC Filing  
9/12/2013David MeekInsiderSell10,000$15.50$155,000.00View SEC Filing  
9/3/2013P Ron EllisCEOSell3,000$14.54$43,620.00View SEC Filing  
8/30/2013Allen RitterVPSell6,000$14.36$86,160.00View SEC Filing  
8/6/2013Chandra LovejoyVPSell7,000$17.29$121,030.00View SEC Filing  
8/1/2013P Ron EllisCEOSell3,000$18.12$54,360.00View SEC Filing  
7/15/2013P Ron EllisCEOSell3,000$17.01$51,030.00View SEC Filing  
5/28/2013Ann HanhamDirectorSell9,900$14.10$139,590.00View SEC Filing  
5/22/2013Ann HanhamDirectorSell40,000$14.38$575,200.00View SEC Filing  
5/17/2013Ann HanhamDirectorSell37,200$14.41$536,052.00View SEC Filing  
5/17/2013Binh NguyenVPSell17,300$14.42$249,466.00View SEC Filing  
5/15/2013Ann HanhamDirectorSell40,200$14.69$590,538.00View SEC Filing  
5/14/2013Christopher P LeamonVPSell5,000$14.70$73,500.00View SEC Filing  
2/25/2013Chandra D LovejoyVPSell2,102$9.70$20,389.40View SEC Filing  
12/26/2012Chandra D LovejoyVPSell2,209$9.05$19,991.45View SEC Filing  
11/26/2012Chandra D LovejoyVPSell2,209$8.72$19,262.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Endocyte (NASDAQ:ECYT)
DateHeadline
zacks.com logoEndocyte (ECYT) to Post Q4 Earnings: What's in the Cards? (NASDAQ:ECYT)
www.zacks.com - February 23 at 4:52 PM
streetinsider.com logoEndocyte (ECYT) Appoints Michael Andriole as CFO (NASDAQ:ECYT)
www.streetinsider.com - February 22 at 5:08 PM
4-traders.com logoEndocyte : Appoints Michael T. Andriole as Chief Financial Officer (NASDAQ:ECYT)
www.4-traders.com - February 22 at 5:08 PM
News IconEquity Check-in on This Stock: Endocyte, Inc. (NASDAQ:ECYT) - Midway Monitor (NASDAQ:ECYT)
midwaymonitor.com - February 22 at 7:16 AM
streetinsider.com logoEndocyte (ECYT) Appoints Michael Andriole as CFO - StreetInsider.com (NASDAQ:ECYT)
www.streetinsider.com - February 22 at 7:16 AM
finance.yahoo.com logoEndocyte Appoints Michael T. Andriole as Chief Financial Officer (NASDAQ:ECYT)
finance.yahoo.com - February 22 at 7:16 AM
finance.yahoo.com logo8:17 am Endocyte appoints Michael T. Andriole as CFO (NASDAQ:ECYT)
finance.yahoo.com - February 22 at 7:16 AM
biz.yahoo.com logoENDOCYTE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:ECYT)
biz.yahoo.com - February 22 at 7:16 AM
News IconWill This Stock Move with Earnings? The Sell-side chimes in on Endocyte, Inc. (NASDAQ:ECYT) Shares - Aiken Advocate (NASDAQ:ECYT)
aikenadvocate.com - February 20 at 4:32 PM
News IconEndocyte Inc ECYT Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:ECYT)
www.bioportfolio.com - February 19 at 4:28 PM
News IconStock Update: Levels in Review for Endocyte Inc. (ECYT) - Piedmont Register (NASDAQ:ECYT)
piedmontregister.com - February 8 at 10:24 PM
News IconTrading Radar: Zooming in on Shares of Endocyte Inc. (ECYT) - Sherwood Daily (NASDAQ:ECYT)
sherwooddaily.com - February 3 at 10:16 PM
News IconAre These Shares a Bargain: Update on Endocyte, Inc. (NASDAQ:ECYT) - Prospect Journal (NASDAQ:ECYT)
prospectjournal.com - February 1 at 3:34 AM
News IconEndocyte, Inc. (ECYT) Could Burn Your Portfolio. The Stock Formed Bearish Wedge Down Chart Pattern (NASDAQ:ECYT)
randolphguide.com - January 31 at 3:55 AM
News IconEquity Focus: Indicator Check on Shares of Endocyte Inc. (ECYT) - Sherwood Daily (NASDAQ:ECYT)
sherwooddaily.com - January 30 at 12:23 PM
News IconNews Impact Score Of Endocyte, Inc. (NASDAQ:ECYT) At 90 - Stock Observer (NASDAQ:ECYT)
www.thestockobserver.com - January 30 at 12:23 PM
News IconMeasuring the Levels on Shares of Endocyte Inc. (ECYT) - Sherwood Daily (NASDAQ:ECYT)
sherwooddaily.com - January 28 at 4:36 AM
News IconStock Review: Checking in on Share of Endocyte, Inc. (NASDAQ:ECYT) - The Tribune (NASDAQ:ECYT)
lakecitytribune.com - January 27 at 6:33 PM
News IconEndocyte Inc ECYT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ECYT)
www.bioportfolio.com - January 26 at 11:13 PM
News IconEndocyte, Inc. (NASDAQ:ECYT) Quarterly EPS Projection At $-0.27 - Stock Observer (NASDAQ:ECYT)
www.thestockobserver.com - January 26 at 6:12 PM
News IconTracking Williams %R for Endocyte Inc. (ECYT) - Sherwood Daily (NASDAQ:ECYT)
sherwooddaily.com - January 26 at 6:12 PM
News IconNews Impact Score Of Endocyte, Inc. (NASDAQ:ECYT) Set At 85 - Stock Observer (NASDAQ:ECYT)
www.thestockobserver.com - January 22 at 4:48 PM
News IconMonitoring Relative Strength Index Values for Endocyte Inc. (ECYT) - Sherwood Daily (NASDAQ:ECYT)
sherwooddaily.com - January 21 at 4:11 AM
News IconKeeping Tabs on Technicals for Endocyte Inc. (ECYT) - Sherwood Daily (NASDAQ:ECYT)
sherwooddaily.com - January 19 at 6:17 PM
News IconChart Indicator Check on Shares of Endocyte Inc. (ECYT) - Sherwood Daily (NASDAQ:ECYT)
sherwooddaily.com - January 18 at 10:18 PM
News IconBargain Hunter's Delight: What's the Latest on Endocyte, Inc. (NASDAQ:ECYT) - Prospect Journal (NASDAQ:ECYT)
prospectjournal.com - January 18 at 10:18 PM
News IconAre Institutions Trimming Down Their Positions In Endocyte, Inc. (NASDAQ:ECYT) - Wall Street Beacon (NASDAQ:ECYT)
wsbeacon.com - January 18 at 10:18 PM
News IconWhat is the Sell-side Saying About Endocyte, Inc. (NASDAQ:ECYT)? - Aiken Advocate (NASDAQ:ECYT)
aikenadvocate.com - January 17 at 8:11 AM
News IconWill The Needle Move For Endocyte, Inc. (NASDAQ:ECYT) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ECYT)
wsbeacon.com - January 17 at 8:11 AM
News IconNews Impact Score Of Endocyte, Inc. (NASDAQ:ECYT) Set At 0 - Stock Observer (NASDAQ:ECYT)
www.thestockobserver.com - January 15 at 9:43 PM
News IconLive Price Coverage: Could Endocyte, Inc. See a Reversal After Breaking All Highs? - Fair View Times (NASDAQ:ECYT)
fairviewtimes.com - January 13 at 5:39 PM
News IconRipe for A Big Move? Update on Endocyte, Inc. (NASDAQ:ECYT) - Prospect Journal (NASDAQ:ECYT)
prospectjournal.com - January 13 at 5:39 PM
News IconRisky Play or Bargain? Update on Endocyte, Inc. (NASDAQ:ECYT) - Prospect Journal (NASDAQ:ECYT)
prospectjournal.com - January 12 at 5:21 PM
News IconEndocyte Inc. (ECYT) Shares Slip, Investors Watching Closely, Here ... - BNB Daily (blog) (NASDAQ:ECYT)
www.baseball-news-blog.com - January 12 at 5:21 PM
News IconDelving into Shares of Endocyte, Inc. (NASDAQ:ECYT) - Prospect Journal (NASDAQ:ECYT)
prospectjournal.com - January 11 at 10:27 PM
News IconAt the Focal Point, Checking in on Endocyte, Inc. (NASDAQ:ECYT) - Prospect Journal (NASDAQ:ECYT)
prospectjournal.com - January 10 at 10:51 PM
News IconEPS Of Endocyte, Inc. (NASDAQ:ECYT) At $-0.27 | Stock Observer - Stock Observer (NASDAQ:ECYT)
www.thestockobserver.com - January 10 at 10:51 PM
finance.yahoo.com logoValeant to Sell Dendreon Unit to Sanpower for $820 Million (NASDAQ:ECYT)
finance.yahoo.com - January 10 at 5:50 PM
News IconEndocyte, Inc. (NASDAQ:ECYT) EPS At $-0.27 - Stock Observer (NASDAQ:ECYT)
www.thestockobserver.com - January 4 at 6:14 AM
News IconPlacing the Bulls-Eye Focus on Endocyte, Inc. (NASDAQ:ECYT) - Prospect Journal (NASDAQ:ECYT)
prospectjournal.com - January 3 at 6:49 PM
News IconStock Spotlight: Checking on Shares of Endocyte, Inc. (NASDAQ:ECYT) - Wall Street Beacon (NASDAQ:ECYT)
wsbeacon.com - January 3 at 6:49 PM
finance.yahoo.com logoIs Valeant (VRX) Fated for Terrible 2017 As Well? (NASDAQ:ECYT)
finance.yahoo.com - January 3 at 6:49 PM
live-pr.com logoEndocyte, Inc. (ECYT) - Financial and Strategic SWOT Analysis Review - New Market Report (NASDAQ:ECYT)
www.live-pr.com - December 30 at 5:16 PM
News IconEndocyte, Inc. (NASDAQ:ECYT) reported actual EPS of -0.21 in the ... - The Newburgh Press (NASDAQ:ECYT)
newburghpress.com - December 21 at 10:42 PM
News IconWhich Direction is This Stock Headed? Update on Endocyte, Inc ... - Prospect Journal (NASDAQ:ECYT)
prospectjournal.com - December 21 at 10:42 PM
News IconEquity in Focus: Endocyte, Inc. (NASDAQ:ECYT) - Liberty News (NASDAQ:ECYT)
libertynewsrecord.com - December 21 at 10:42 PM
News IconHow Endocyte, Inc. (ECYT) Stacks Up Against Its Peers (NASDAQ:ECYT)
feedproxy.google.com - December 15 at 9:13 PM
capitalcube.com logoETFs with exposure to Endocyte, Inc. : December 14, 2016 (NASDAQ:ECYT)
www.capitalcube.com - December 14 at 5:56 PM
News IconEPS Of Endocyte, Inc. (NASDAQ:ECYT) Set At $-0.27 - Stock Observer (NASDAQ:ECYT)
www.thestockobserver.com - December 14 at 3:37 AM
News IconLooking at the Numbers for Endocyte, Inc. (NASDAQ:ECYT) - Liberty News (NASDAQ:ECYT)
libertynewsrecord.com - December 14 at 3:37 AM

Social

What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

Where is Endocyte's stock going? Where will Endocyte's stock price be in 2017?

3 equities research analysts have issued 1 year price objectives for Endocyte's shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Endocyte's stock price to reach $7.50 in the next twelve months.

When will Endocyte announce their earnings?

Endocyte is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

Who owns Endocyte stock?

Endocyte's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (8.24%), Pinnacle Associates Ltd. (1.94%), State Street Corp (1.47%), Highland Capital Management LP (1.09%), Oxford Asset Management (0.50%) and Employees Retirement System of Texas (0.32%). Company insiders that own Endocyte stock include Christopher P Leamon, Fred A Middleton and Philip S Low.

Who sold Endocyte stock? Who is selling Endocyte stock?

Endocyte's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Pinnacle Associates Ltd. and Highland Capital Management LP.

Who bought Endocyte stock? Who is buying Endocyte stock?

Endocyte's stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management, Two Sigma Investments LP, FMR LLC and State Street Corp. Company insiders that have bought Endocyte stock in the last two years include Fred A Middleton and Philip S Low.

How do I buy Endocyte stock?

Shares of Endocyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Endocyte stock cost?

One share of Endocyte stock can currently be purchased for approximately $2.04.

Endocyte (NASDAQ:ECYT) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Endocyte (NASDAQ:ECYT)

Earnings History Chart

Earnings by Quarter for Endocyte (NASDAQ:ECYT)

Dividend History Chart

Dividend Payments by Quarter for Endocyte (NASDAQ:ECYT)

Last Updated on 2/26/2017 by MarketBeat.com Staff